MTOR and gastric cancer: Although responses of ZSTK474 (Cor: 0.199, p = 0.002) and GSK690693 (Cor: 0.194, p < 0.0001) did not reach a significant correlation with the RS score, it was interesting that the high-risk group with EMT features was also sensitized to PI3K/mTOR inhibitors, suggesting that the risk score–based stratification had the reliable capability to predict therapeutical response of individual GC patients.